PedAM
Pediatric Disease Annotations & Medicines
| leukemia, acute myeloid | ||||
| Disease ID | 690 |
|---|---|
| Disease | leukemia, acute myeloid |
| Definition | acute leukemia arising from myeloid tissue in which the granular, polymorphonuclear leukocytes and their precursors predominate. |
| Synonym | [m]acute myeloid leukaemia [m]acute myeloid leukaemia (disorder) [m]acute myeloid leukemia acute granulocytic leukaemia acute granulocytic leukemia acute leukemias non lymphoblastic acute myeloblastic leukaemia acute myeloblastic leukemia acute myeloblastic leukemia (disorder) acute myeloblastic leukemias acute myelocytic leukaemia acute myelocytic leukemia acute myelocytic leukemias acute myelogenous leukaemia acute myelogenous leukemia acute myelogenous leukemia (aml) acute myelogenous leukemias acute myeloid leukaemia acute myeloid leukaemia - category acute myeloid leukaemia, disease acute myeloid leukaemia, no icd-o subtype acute myeloid leukemia acute myeloid leukemia - category acute myeloid leukemia - category (morphologic abnormality) acute myeloid leukemia nos acute myeloid leukemia not otherwise categorized acute myeloid leukemia not otherwise specified acute myeloid leukemia, disease acute myeloid leukemia, disease (disorder) acute myeloid leukemia, no icd-o subtype acute myeloid leukemia, no icd-o subtype (morphologic abnormality) acute myeloid leukemia, no international classification of diseases for oncology subtype acute myeloid leukemia, no international classification of diseases for oncology subtype (morphologic abnormality) acute myeloid leukemia, nos acute myeloid leukemias acute non-lymphoblastic leukemia acute non-lymphocytic leukaemia acute non-lymphocytic leukemia acute nonlymphoblastic leukemia acute nonlymphoblastic leukemias acute nonlymphocytic leukemia acute nonlymphocytic leukemia (anll) acute nonlymphocytic leukemias aml aml - acute myeloblastic leukaemia aml - acute myeloblastic leukemia aml - acute myeloid leukaemia aml - acute myeloid leukemia aml, nos anll hematopoeitic - acute myleogenous leukemia (aml) leukemia acute myeloblastic leukemia myeloblastic acute leukemia, acute myeloblastic leukemia, acute myelocytic leukemia, acute myelogenous leukemia, acute nonlymphoblastic leukemia, acute nonlymphocytic leukemia, granulocytic, acute leukemia, myeloblastic, acute leukemia, myelocytic, acute leukemia, myelogenous, acute leukemia, myeloid, acute leukemia, myeloid, acute [disease/finding] leukemia, nonlymphoblastic, acute leukemia, nonlymphocytic, acute leukemias, acute myeloblastic leukemias, acute myelocytic leukemias, acute myelogenous leukemias, acute myeloid leukemias, acute nonlymphoblastic leukemias, acute nonlymphocytic myeloblastic leukemia, acute myeloblastic leukemias, acute myelocytic leukemia, acute myelocytic leukemias, acute myelogenous leukemia, acute myelogenous leukemias, acute myeloid leukemia, acute myeloid leukemias, acute non-lymphoblastic leukemia acute nonlymphoblastic leukemia, acute nonlymphoblastic leukemias, acute nonlymphocytic leukemia, acute nonlymphocytic leukemias, acute |
| Orphanet | |
| OMIM | |
| DOID | |
| UMLS | C0023467 |
| MeSH | |
| SNOMED-CT | |
| Curated Gene | Entrez_id | Symbol | Resource(Total Genes:118) GATA2 | 2624 | CTD_human;ORPHANET STAT5B | 6777 | GHR BACH2 | 60468 | CTD_human KIT | 3815 | CLINVAR;CTD_human FAS | 355 | CTD_human BCL2 | 596 | CTD_human STAT3 | 6774 | CTD_human VOPP1 | 81552 | CTD_human MET | 4233 | CTD_human MYC | 4609 | CTD_human NF1 | 4763 | CTD_human SETBP1 | 26040 | UNIPROT ID2 | 3398 | CTD_human SVIL | 6840 | CTD_human RUNX1 | 861 | CTD_human RUNX3 | 864 | CTD_human MYH11 | 4629 | CTD_human WT1 | 7490 | CTD_human CSF2 | 1437 | CTD_human TRIO | 7204 | CTD_human TNFSF10 | 8743 | CTD_human CST3 | 1471 | CTD_human TERT | 7015 | CLINVAR GFI1 | 2672 | CTD_human CASP7 | 840 | CTD_human MX1 | 4599 | CTD_human TSC2 | 7249 | CTD_human CSF3 | 1440 | CTD_human KMT2C | 58508 | CTD_human KMT2A | 4297 | CTD_human ANXA2 | 302 | CTD_human HGF | 3082 | CTD_human MLLT10 | 8028 | CTD_human FXYD6 | 53826 | CTD_human RASGRP1 | 10125 | CTD_human CDK6 | 1021 | CTD_human ATP1B1 | 481 | CTD_human JAK2 | 3717 | CTD_human;UNIPROT TCEA2 | 6919 | CTD_human KRAS | 3845 | CLINVAR RARA | 5914 | GHR SPI1 | 6688 | CTD_human SPRY4 | 81848 | CTD_human NSD1 | 64324 | CTD_human CEBPD | 1052 | CTD_human SPARC | 6678 | CTD_human NUMA1 | 4926 | GHR ETV6 | 2120 | CLINVAR;CTD_human SYNGR1 | 9145 | CTD_human FOXO1 | 2308 | CTD_human AGRN | 375790 | CTD_human HOXA9 | 3205 | CTD_human EIF4EBP1 | 1978 | CTD_human ENO2 | 2026 | CTD_human POU4F1 | 5457 | CTD_human NUP214 | 8021 | CTD_human PDE4B | 5142 | CTD_human PICALM | 8301 | CTD_human ZBTB16 | 7704 | GHR ANXA5 | 308 | CTD_human IFI30 | 10437 | CTD_human CAPN2 | 824 | CTD_human S100A10 | 6281 | CTD_human LPAR1 | 1902 | CTD_human NUP98 | 4928 | CTD_human CD44 | 960 | CTD_human ARHGEF12 | 23365 | CTD_human HSPB1 | 3315 | CTD_human SGK1 | 6446 | CTD_human FLT3 | 2322 | CLINVAR;CTD_human TRH | 7200 | CTD_human PXDN | 7837 | CTD_human PML | 5371 | GHR MN1 | 4330 | CTD_human ANXA4 | 307 | CTD_human ASMTL | 8623 | CTD_human RGS2 | 5997 | CTD_human DAPK1 | 1612 | CTD_human VSIG4 | 11326 | CTD_human ENAH | 55740 | CTD_human PIM2 | 11040 | CTD_human CNR2 | 1269 | CTD_human CTNNA1 | 1495 | CTD_human H1F0 | 3005 | CTD_human TUBB2A | 7280 | CTD_human ADCY7 | 113 | CTD_human CAPG | 822 | CTD_human TGM6 | 343641 | CLINVAR NPM1 | 4869 | CLINVAR;CTD_human;GHR ERG | 2078 | CTD_human AMLCR2 | 9163 | CTD_human CBFB | 865 | CTD_human CD9 | 928 | CTD_human CTSH | 1512 | CTD_human DDX41 | 51428 | CLINVAR LYL1 | 4066 | CTD_human LPP | 4026 | CTD_human GTF2I | 2969 | CTD_human SH3GL1 | 6455 | CTD_human GAS2L1 | 10634 | CTD_human CTSZ | 1522 | CTD_human CSF1R | 1436 | CTD_human CD33 | 945 | CTD_human AQP9 | 366 | CTD_human S100A8 | 6279 | CTD_human DLEU2 | 8847 | CTD_human BAALC | 79870 | CTD_human CEBPA | 1050 | CLINVAR;CTD_human;UNIPROT RUNX1T1 | 862 | CTD_human ANXA6 | 309 | CTD_human EHD3 | 30845 | CTD_human GMPS | 8833 | CTD_human PSIP1 | 11168 | CTD_human HIST1H1C | 3006 | CTD_human CHIC2 | 26511 | CTD_human MLF1 | 4291 | CTD_human FHL2 | 2274 | CTD_human CHMP5 | 51510 | CTD_human |
| Inferring Gene | Entrez_id | Symbol | Resource(Total Genes:55) 1050 | CEBPA | infer 355 | FAS | infer 2322 | FLT3 | infer 4292 | MLH1 | infer 5243 | ABCB1 | infer 978 | CDA | infer 2067 | ERCC1 | infer 2068 | ERCC2 | infer 2073 | ERCC5 | infer 2952 | GSTT1 | infer 8856 | NR1I2 | infer 6819 | SULT1C2 | infer 7153 | TOP2A | infer 7422 | VEGFA | infer 7507 | XPA | infer 3717 | JAK2 | infer 2052 | EPHX1 | infer 2944 | GSTM1 | infer 3815 | KIT | infer 3845 | KRAS | infer 4353 | MPO | infer 1728 | NQO1 | infer 8714 | ABCC3 | infer 9429 | ABCG2 | infer 332 | BIRC5 | infer 902 | CCNH | infer 1577 | CYP3A5 | infer 780 | DDR1 | infer 1788 | DNMT3A | infer 356 | FASLG | infer 2950 | GSTP1 | infer 3417 | IDH1 | infer 3418 | IDH2 | infer 3716 | JAK1 | infer 4193 | MDM2 | infer 9 | NAT1 | infer 10 | NAT2 | infer 4763 | NF1 | infer 4869 | NPM1 | infer 4893 | NRAS | infer 4914 | NTRK1 | infer 5781 | PTPN11 | infer 5888 | RAD51 | infer 5921 | RASA1 | infer 861 | RUNX1 | infer 9154 | SLC28A1 | infer 6654 | SOS1 | infer 6688 | SPI1 | infer 7012 | TERC | infer 7015 | TERT | infer 7157 | TP53 | infer 7297 | TYK2 | infer 7490 | WT1 | infer 7508 | XPC | infer 7517 | XRCC3 | infer |
| Text Mined Gene | (Waiting for update.) |
| Locus | (Waiting for update.) |
| Disease ID | 690 |
|---|---|
| Disease | leukemia, acute myeloid |
| Integrated Phenotype | HPO | Name(Total Integrated Phenotypes:1) HP:0004808 | Acute myelogenous leukemia |
| Text Mined Phenotype | (Waiting for update.) |
| Disease ID | 690 |
|---|---|
| Disease | leukemia, acute myeloid |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | (Waiting for update.) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:207) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1042522 | 20232390 | 7157 | TP53 | umls:C0023467 | BeFree | Postchemotherapy response analysis revealed that AML patients heterozygous for ATM 4138C>T (rs3092856) or GG homozygous for TP53 215C>G (rs1042522) were independently linked to inferior treatment outcomes. | 0.156878977 | 2011 | TP53 | 17 | 7676154 | G | T,C |
| rs10514611 | 24886876 | 23092 | ARHGAP26 | umls:C0023467 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.001628651 | 2014 | IRF8 | 16 | 85921636 | C | T |
| rs10514611 | 24886876 | 5371 | PML | umls:C0023467 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.011943442 | 2014 | IRF8 | 16 | 85921636 | C | T |
| rs10514611 | 24886876 | 3394 | IRF8 | umls:C0023467 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.001628651 | 2014 | IRF8 | 16 | 85921636 | C | T |
| rs1078327 | 21573891 | 64127 | NOD2 | umls:C0023467 | BeFree | However, a weak association between a single nucleotide polymorphism in the NOD2 gene (R471C) and acute myeloid leukemia in the bone marrow patients (p = 0.029, odds ratio 4.08, 95% CI 1.22-13.67) was detected. | 0.005276948 | 2011 | NOD2 | 16 | 50711322 | C | T |
| rs10821936 | 24564228 | 1053 | CEBPE | umls:C0023467 | BeFree | The SNPs (IKZF1 rs11978267, ARID5B rs10821936 and rs10994982, CEBPE rs2239633) were genotyped in 265 cases [169 acute lymphoblastic leukemia (ALL) and 96 acute myeloid leukaemia (AML)] and 505 controls by Taqman allelic discrimination assay. | 0.003538676 | 2014 | ARID5B | 10 | 61963818 | C | T |
| rs10821936 | 24564228 | 84159 | ARID5B | umls:C0023467 | BeFree | The SNPs (IKZF1 rs11978267, ARID5B rs10821936 and rs10994982, CEBPE rs2239633) were genotyped in 265 cases [169 acute lymphoblastic leukemia (ALL) and 96 acute myeloid leukaemia (AML)] and 505 controls by Taqman allelic discrimination assay. | 0.000271442 | 2014 | ARID5B | 10 | 61963818 | C | T |
| rs10994982 | 24564228 | 1053 | CEBPE | umls:C0023467 | BeFree | The SNPs (IKZF1 rs11978267, ARID5B rs10821936 and rs10994982, CEBPE rs2239633) were genotyped in 265 cases [169 acute lymphoblastic leukemia (ALL) and 96 acute myeloid leukaemia (AML)] and 505 controls by Taqman allelic discrimination assay. | 0.003538676 | 2014 | ARID5B | 10 | 61950345 | A | G |
| rs10994982 | 24564228 | 84159 | ARID5B | umls:C0023467 | BeFree | The SNPs (IKZF1 rs11978267, ARID5B rs10821936 and rs10994982, CEBPE rs2239633) were genotyped in 265 cases [169 acute lymphoblastic leukemia (ALL) and 96 acute myeloid leukaemia (AML)] and 505 controls by Taqman allelic discrimination assay. | 0.000271442 | 2014 | ARID5B | 10 | 61950345 | A | G |
| rs111033557 | 15863206 | 7036 | TFR2 | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000814326 | 2005 | HFE | 6 | 26090939 | G | A |
| rs111033557 | 15863206 | 3077 | HFE | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.001357209 | 2005 | HFE | 6 | 26090939 | G | A |
| rs111033563 | 15863206 | 7036 | TFR2 | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000814326 | 2005 | HFE | 6 | 26092916 | A | C |
| rs111033563 | 15863206 | 3077 | HFE | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.001357209 | 2005 | HFE | 6 | 26092916 | A | C |
| rs11554137 | 20368538 | 3417 | IDH1 | umls:C0023467 | GAD | [IDH1 exon four was directly sequenced in 275 CN-AML patients from two subsequent AML multicenter treatment trials and 120 healthy volunteers.] | 0.051205501 | 2010 | IDH1 | 2 | 208248468 | G | A |
| rs11554137 | 23184331 | 3417 | IDH1 | umls:C0023467 | BeFree | rs11554137:C>T) located on IDH1 codon 105 has been associated with a poor outcome in patients with acute myeloid leukemia but has not been investigated in patients with gliomas. | 0.051205501 | 2013 | IDH1 | 2 | 208248468 | G | A |
| rs11554137 | 21873548 | 3417 | IDH1 | umls:C0023467 | BeFree | IDH1 SNP rs11554137 was recently reported in association with poor prognosis in normal karyotype adult acute myeloid leukemia (AML). | 0.051205501 | 2011 | IDH1 | 2 | 208248468 | G | A |
| rs11978267 | 24564228 | 1053 | CEBPE | umls:C0023467 | BeFree | The SNPs (IKZF1 rs11978267, ARID5B rs10821936 and rs10994982, CEBPE rs2239633) were genotyped in 265 cases [169 acute lymphoblastic leukemia (ALL) and 96 acute myeloid leukaemia (AML)] and 505 controls by Taqman allelic discrimination assay. | 0.003538676 | 2014 | IKZF1;LOC105375275 | 7 | 50398606 | A | G |
| rs11978267 | 24564228 | 84159 | ARID5B | umls:C0023467 | BeFree | The SNPs (IKZF1 rs11978267, ARID5B rs10821936 and rs10994982, CEBPE rs2239633) were genotyped in 265 cases [169 acute lymphoblastic leukemia (ALL) and 96 acute myeloid leukaemia (AML)] and 505 controls by Taqman allelic discrimination assay. | 0.000271442 | 2014 | IKZF1;LOC105375275 | 7 | 50398606 | A | G |
| rs121434637 | NA | 2120 | ETV6 | umls:C0023467 | CLINVAR | NA | 0.2605735 | NA | ETV6 | 12 | 11839202 | G | T |
| rs121909646 | NA | 2322 | FLT3 | umls:C0023467 | CLINVAR | NA | 0.56 | NA | FLT3 | 13 | 28018504 | T | A |
| rs121912791 | NA | 1050 | CEBPA | umls:C0023467 | CLINVAR | NA | 0.553105144 | NA | CEBPA;CEBPA-AS1 | 19 | 33302267 | C | A |
| rs121913237 | 21163920 | 4893 | NRAS | umls:C0023467 | BeFree | Injecting Mx1-Cre, LSL-Nras(G12D) mice with the MOL4070LTR retrovirus causes acute myeloid leukemia that faithfully recapitulates many aspects of human NRAS-associated leukemias, including cooperation with deregulated Evi1 expression. | 0.038651823 | 2011 | NRAS | 1 | 114716126 | C | T,G,A |
| rs121913237 | 25316678 | 4893 | NRAS | umls:C0023467 | BeFree | To elucidate the downstream functions of activated NRAS in AML, we used a murine model that harbors Mll-AF9 and a tetracycline-repressible, activated NRAS (NRAS(G12V)). | 0.038651823 | 2015 | NRAS | 1 | 114716126 | C | T,G,A |
| rs121913486 | NA | 2322 | FLT3 | umls:C0023467 | CLINVAR | NA | 0.56 | NA | FLT3 | 13 | 28018503 | ATC | - |
| rs121913488 | NA | 2322 | FLT3 | umls:C0023467 | CLINVAR | NA | 0.56 | NA | FLT3 | 13 | 28018505 | C | T,G,A |
| rs121913488 | 22354205 | 2322 | FLT3 | umls:C0023467 | BeFree | Our FLT3-Aurora kinase inhibitor, CCT137690, successfully inhibited growth of FLT3-ITD-D835Y cells in vitro and in vivo, suggesting that dual FLT3-Aurora inhibition may overcome selective FLT3 inhibitor resistance, in part due to inhibition of Aurora kinase, and may benefit patients with FLT3-mutated AML. | 0.56 | 2012 | FLT3 | 13 | 28018505 | C | T,G,A |
| rs121913499 | 20142433 | 3417 | IDH1 | umls:C0023467 | BeFree | The IDH1 R132C mutation commonly found in AML reduces the affinity for isocitrate, and increases the affinity for NADPH and alpha-KG. | 0.051205501 | 2010 | IDH1 | 2 | 208248389 | G | T,A |
| rs121913499 | 20410924 | 3417 | IDH1 | umls:C0023467 | BeFree | IDH1 mutations included R132C (n=4; two post-PMF AML, one post-PV AML and one PMF) and R132S (n=1; post-PMF AML). | 0.051205501 | 2010 | IDH1 | 2 | 208248389 | G | T,A |
| rs121913499 | 22323113 | 3417 | IDH1 | umls:C0023467 | BeFree | The frequency of IDH1/2 mutations was 56%, and the IDH1 R132C mutation, which is not common in diffuse gliomas or AML, accounted for 40% of these mutations. | 0.051205501 | 2012 | IDH1 | 2 | 208248389 | G | T,A |
| rs121913500 | 23111200 | 3417 | IDH1 | umls:C0023467 | BeFree | The IDH1 R132H point mutation is common in gliomas and acute myelogenous leukemia, but this has not been previously reported in breast carcinoma. | 0.051205501 | 2012 | IDH1 | 2 | 208248388 | C | T |
| rs121913500 | 25599133 | 3417 | IDH1 | umls:C0023467 | BeFree | Here we performed a large-scale RNA interference (RNAi) screen to identify genes that are synthetic lethal to the IDH1(R132H) mutation in AML and identified the anti-apoptotic gene BCL-2. | 0.051205501 | 2014 | IDH1 | 2 | 208248388 | C | T |
| rs121913500 | 22172803 | 3417 | IDH1 | umls:C0023467 | BeFree | Detection of IDH1 R132H mutation in acute myeloid leukemia by mutation-specific immunohistochemistry. | 0.051205501 | 2012 | IDH1 | 2 | 208248388 | C | T |
| rs121913502 | 25795706 | 2322 | FLT3 | umls:C0023467 | BeFree | To determine whether mutant IDH enzymes are valid targets for cancer therapy, we created a mouse model of AML in which mice were transplanted with nucleophosmin1 (NPM)(+/-) hematopoietic stem/progenitor cells cotransduced with four mutant genes (NPMc, IDH2/R140Q, DNMT3A/R882H, and FLT3/ITD), which often occur simultaneously in human AML patients. | 0.56 | 2015 | IDH2 | 15 | 90088702 | C | T |
| rs121913502 | 25795706 | 1788 | DNMT3A | umls:C0023467 | BeFree | To determine whether mutant IDH enzymes are valid targets for cancer therapy, we created a mouse model of AML in which mice were transplanted with nucleophosmin1 (NPM)(+/-) hematopoietic stem/progenitor cells cotransduced with four mutant genes (NPMc, IDH2/R140Q, DNMT3A/R882H, and FLT3/ITD), which often occur simultaneously in human AML patients. | 0.017567777 | 2015 | IDH2 | 15 | 90088702 | C | T |
| rs121913502 | 23949315 | 3418 | IDH2 | umls:C0023467 | BeFree | Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia. | 0.035765652 | 2013 | IDH2 | 15 | 90088702 | C | T |
| rs121913503 | 23949315 | 3418 | IDH2 | umls:C0023467 | BeFree | Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia. | 0.035765652 | 2013 | IDH2 | 15 | 90088606 | C | T |
| rs121913504 | 25109334 | 3718 | JAK3 | umls:C0023467 | BeFree | Using this screen, we identified interleukin-2 gamma receptor (IL2Rγ) as a critical growth determinant for a JAK3(A572V) mutation-positive acute myeloid leukemia cell line. | 0.000542884 | 2014 | JAK3 | 19 | 17837200 | G | A |
| rs121913504 | 25109334 | 9913 | SUPT7L | umls:C0023467 | BeFree | Using this screen, we identified interleukin-2 gamma receptor (IL2Rγ) as a critical growth determinant for a JAK3(A572V) mutation-positive acute myeloid leukemia cell line. | 0.002171535 | 2014 | JAK3 | 19 | 17837200 | G | A |
| rs121913504 | 25109334 | 3558 | IL2 | umls:C0023467 | BeFree | Using this screen, we identified interleukin-2 gamma receptor (IL2Rγ) as a critical growth determinant for a JAK3(A572V) mutation-positive acute myeloid leukemia cell line. | 0.005971721 | 2014 | JAK3 | 19 | 17837200 | G | A |
| rs121913506 | NA | 3815 | KIT | umls:C0023467 | CLINVAR | NA | 0.301492667 | NA | KIT | 4 | 54733154 | G | C,T |
| rs121913507 | 12393643 | 3815 | KIT | umls:C0023467 | BeFree | Substitution of valine (Val) for aspartic acid (Asp) at codon 814 constitutively activates murine c-kit receptor tyrosine kinase (KIT), and Asp816Val mutation, corresponding to murine Asp814Val mutation, is found in patients with mastocytosis and acute myelocytic leukemia. | 0.301492667 | 2003 | KIT | 4 | 54733155 | A | T |
| rs121913507 | 20471335 | 3815 | KIT | umls:C0023467 | BeFree | High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. | 0.301492667 | 2010 | KIT | 4 | 54733155 | A | T |
| rs121913507 | 22145956 | 10153 | CEBPZ | umls:C0023467 | BeFree | The presence of the KIT D816V mutation in the CBF AML subgroup can therefore not be considered indicative of associated SM. | 0.005700279 | 2012 | KIT | 4 | 54733155 | A | T |
| rs121913507 | 17065430 | 3815 | KIT | umls:C0023467 | BeFree | Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. | 0.301492667 | 2006 | KIT | 4 | 54733155 | A | T |
| rs121913507 | 18986703 | 3815 | KIT | umls:C0023467 | BeFree | Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. | 0.301492667 | 2009 | KIT | 4 | 54733155 | A | T |
| rs121913514 | 20227111 | 3815 | KIT | umls:C0023467 | BeFree | The t(8;21) Acute Myeloid Leukaemia (AML) Kasumi-1 cell line with N822K KIT mutation, is a model system for leukemogenesis. | 0.301492667 | 2010 | KIT | 4 | 54733174 | T | A |
| rs121913514 | 16213582 | 3815 | KIT | umls:C0023467 | BeFree | Kasumi-1 is t(8;21) acute myeloid leukemia (AML) cell line harboring mutated KIT with Asn822Lys substitution. | 0.301492667 | 2006 | KIT | 4 | 54733174 | T | A |
| rs121918464 | 21930766 | 5781 | PTPN11 | umls:C0023467 | BeFree | Moreover, tissue-specific knock-in of Ptpn11(E76K/+) mutation in lineage-committed myeloid, T lymphoid, and B lymphoid progenitors also results in AML, T-ALL, and B-ALL, respectively. | 0.012430244 | 2011 | PTPN11 | 12 | 112450406 | G | A,C |
| rs12343867 | 21791467 | 3717 | JAK2 | umls:C0023467 | BeFree | Janus kinase 2 rs12343867 single nucleotide polymorphism tagging the 46/1 haplotype was genotyped by LightCycler technology applying melting curve analysis with the hybridization probe detection format in 176 patients with acute myeloid leukemia under 60 years diagnosed consecutively and treated with curative intent. | 0.284782823 | 2011 | JAK2;INSL6 | 9 | 5074189 | T | C |
| rs13181 | 24284041 | 2068 | ERCC2 | umls:C0023467 | BeFree | XPD Lys751Gln and not Asp312Asn polymorphism was associated with chemotherapy-induced cardiotoxicity and response to induction chemotherapy in newly diagnosed cytogenetically normal AML patients. | 0.011454097 | 2015 | ERCC2;KLC3 | 19 | 45351661 | T | A,G |
| rs137852728 | NA | 1050 | CEBPA | umls:C0023467 | CLINVAR | NA | 0.553105144 | NA | CEBPA;CEBPA-AS1 | 19 | 33302347 | G | - |
| rs137852729 | NA | 1050 | CEBPA | umls:C0023467 | CLINVAR | NA | 0.553105144 | NA | CEBPA;CEBPA-AS1 | 19 | 33302346 | - | G |
| rs137852730 | NA | 1050 | CEBPA | umls:C0023467 | CLINVAR | NA | 0.553105144 | NA | CEBPA;CEBPA-AS1 | 19 | 33302274 | G | - |
| rs137852731 | NA | 1050 | CEBPA | umls:C0023467 | CLINVAR | NA | 0.553105144 | NA | CEBPA;CEBPA-AS1 | 19 | 33302213 | - | GTAG |
| rs137852732 | NA | 1050 | CEBPA | umls:C0023467 | CLINVAR | NA | 0.553105144 | NA | CEBPA;CEBPA-AS1 | 19 | 33302095 | - | CA |
| rs137852733 | NA | 1050 | CEBPA | umls:C0023467 | CLINVAR | NA | 0.553105144 | NA | CEBPA;CEBPA-AS1 | 19 | 33302197 | - | G |
| rs146519482 | 15863206 | 3077 | HFE | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.001357209 | 2005 | HFE | 6 | 26091475 | G | C,T |
| rs146519482 | 15863206 | 7036 | TFR2 | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000814326 | 2005 | HFE | 6 | 26091475 | G | C,T |
| rs147001633 | 25795706 | 2322 | FLT3 | umls:C0023467 | BeFree | To determine whether mutant IDH enzymes are valid targets for cancer therapy, we created a mouse model of AML in which mice were transplanted with nucleophosmin1 (NPM)(+/-) hematopoietic stem/progenitor cells cotransduced with four mutant genes (NPMc, IDH2/R140Q, DNMT3A/R882H, and FLT3/ITD), which often occur simultaneously in human AML patients. | 0.56 | 2015 | DNMT3A | 2 | 25234373 | C | A,G,T |
| rs147001633 | 25795706 | 1788 | DNMT3A | umls:C0023467 | BeFree | To determine whether mutant IDH enzymes are valid targets for cancer therapy, we created a mouse model of AML in which mice were transplanted with nucleophosmin1 (NPM)(+/-) hematopoietic stem/progenitor cells cotransduced with four mutant genes (NPMc, IDH2/R140Q, DNMT3A/R882H, and FLT3/ITD), which often occur simultaneously in human AML patients. | 0.017567777 | 2015 | DNMT3A | 2 | 25234373 | C | A,G,T |
| rs147001633 | 24656771 | 1788 | DNMT3A | umls:C0023467 | BeFree | The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. | 0.017567777 | 2014 | DNMT3A | 2 | 25234373 | C | A,G,T |
| rs1569686 | 24069326 | 7204 | TRIO | umls:C0023467 | BeFree | The CGGT, CTAT, TGAT, and CGAT haplotypes of rs6087990, rs1569686, rs6119954, and rs2424908 appeared to significantly increase the AML risk, and the TTGC haplotype appeared to significantly reduce the risk. | 0.120271442 | 2013 | DNMT3B | 20 | 32779273 | G | C,T |
| rs1569686 | 24069326 | 1789 | DNMT3B | umls:C0023467 | BeFree | These results suggest that DNMT3B polymorphisms may contribute to the genetic susceptibility to AML; in particular, the G allele of rs1569686 serves as a risk factor for AML, whereas the C allele of rs2424908 represents a potential protective factor. | 0.001357209 | 2013 | DNMT3B | 20 | 32779273 | G | C,T |
| rs1569686 | 24069326 | 6570 | SLC18A1 | umls:C0023467 | BeFree | The CGGT, CTAT, TGAT, and CGAT haplotypes of rs6087990, rs1569686, rs6119954, and rs2424908 appeared to significantly increase the AML risk, and the TTGC haplotype appeared to significantly reduce the risk. | 0.000271442 | 2013 | DNMT3B | 20 | 32779273 | G | C,T |
| rs16754 | 23550990 | 7490 | WT1 | umls:C0023467 | BeFree | The single nucleotide polymorphism (SNP) rs16754 of the WT1 gene has been described as a possible prognostic marker in patients with acute myeloid leukemia (AML). | 0.174303151 | 2014 | WT1 | 11 | 32396399 | T | C |
| rs16754 | 23070125 | 7490 | WT1 | umls:C0023467 | BeFree | The single nucleotide polymorphism (SNP) rs16754 of the WT1 gene has been previously described as a possible prognostic marker in normal karyotype acute myeloid leukemia (AML) patients. | 0.174303151 | 2012 | WT1 | 11 | 32396399 | T | C |
| rs16754 | 25841655 | 7490 | WT1 | umls:C0023467 | BeFree | Wilms Tumor 1 rs16754 predicts favorable clinical outcomes for acute myeloid leukemia patients in South Chinese population. | 0.174303151 | 2015 | WT1 | 11 | 32396399 | T | C |
| rs16754 | 21189390 | 7490 | WT1 | umls:C0023467 | BeFree | To analyze the prevalence and clinical implications of Wilms' tumor 1 (WT1) single nucleotide polymorphism (SNP) rs16754 in the context of other prognostic markers in pediatric acute myeloid leukemia (AML). | 0.174303151 | 2011 | WT1 | 11 | 32396399 | T | C |
| rs17166050 | 24093751 | 10111 | RAD50 | umls:C0023467 | BeFree | The frequency of either the AA genotype or A allele of RAD50_rs17166050 were significantly different in controls compared to leukemia group (ALL+AML) (p<0.0019 and p<0.0019, respectively). | 0.000271442 | 2013 | RAD50 | 5 | 132579521 | G | A |
| rs17433222 | 20438785 | 714 | C1QC | umls:C0023467 | GAD | [Polymorphisms in innate immunity genes and risk of childhood leukemia.] | 0.002367032 | 2010 | C1QB | 1 | 22652153 | G | A |
| rs1799782 | 23662987 | 7515 | XRCC1 | umls:C0023467 | BeFree | XRCC1 Arg194Trp and Arg399Gln polymorphisms are significantly associated with shorter survival in acute myeloid leukemia. | 0.00827274 | 2014 | XRCC1 | 19 | 43553422 | G | A |
| rs1799793 | 24284041 | 2068 | ERCC2 | umls:C0023467 | BeFree | XPD Lys751Gln and not Asp312Asn polymorphism was associated with chemotherapy-induced cardiotoxicity and response to induction chemotherapy in newly diagnosed cytogenetically normal AML patients. | 0.011454097 | 2015 | ERCC2 | 19 | 45364001 | C | T |
| rs1799945 | 15863206 | 7036 | TFR2 | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000814326 | 2005 | HFE | 6 | 26090951 | C | G |
| rs1799945 | 15863206 | 3077 | HFE | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.001357209 | 2005 | HFE | 6 | 26090951 | C | G |
| rs1800562 | 15863206 | 3077 | HFE | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.001357209 | 2005 | HFE | 6 | 26092913 | G | A |
| rs1800562 | 15863206 | 7036 | TFR2 | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000814326 | 2005 | HFE | 6 | 26092913 | G | A |
| rs1800562 | 11836162 | 3077 | HFE | umls:C0023467 | BeFree | The divergent frequencies observed for the C282Y mutation in patients with AML and ET highlight the need for larger population studies of HFE mutations in patients with hematologic diseases. | 0.001357209 | 2002 | HFE | 6 | 26092913 | G | A |
| rs1800566 | 22976839 | 5444 | PON1 | umls:C0023467 | BeFree | The NQO1 rs1800566 (C609T), PON1 rs854560 (L55M), and PON1 rs662 (Q192R) polymorphisms modified risk depending on leukemia subtype (decreased in AML, increased and decreased in ALL, respectively), age strata, and variant genotype combinations. | 0.000271442 | 2012 | NQO1 | 16 | 69711242 | G | A |
| rs1800713 | 17367411 | 1543 | CYP1A1 | umls:C0023467 | BeFree | We analysed the prevalence of genetic polymorphisms of CYP1A1*2A(T6235C), CYP2E1*5B(C-1019T), CYP3A4*1B(A-290G), del{GSTT1}, del{GSTM1}, NQO1*2(C609T), MTHFR(C677T) and TYMS 2R/3R in 78 t-AML/t-MDS and 458 normal individuals (control group, CG) using real-time and conventional polymerase chain reaction (PCR)-based methods. | 0.007262917 | 2007 | CYP3A4 | 7 | 99784371 | T | C |
| rs1800713 | 17367411 | 4524 | MTHFR | umls:C0023467 | BeFree | We analysed the prevalence of genetic polymorphisms of CYP1A1*2A(T6235C), CYP2E1*5B(C-1019T), CYP3A4*1B(A-290G), del{GSTT1}, del{GSTM1}, NQO1*2(C609T), MTHFR(C677T) and TYMS 2R/3R in 78 t-AML/t-MDS and 458 normal individuals (control group, CG) using real-time and conventional polymerase chain reaction (PCR)-based methods. | 0.016731045 | 2007 | CYP3A4 | 7 | 99784371 | T | C |
| rs1800713 | 17367411 | 7298 | TYMS | umls:C0023467 | BeFree | We analysed the prevalence of genetic polymorphisms of CYP1A1*2A(T6235C), CYP2E1*5B(C-1019T), CYP3A4*1B(A-290G), del{GSTT1}, del{GSTM1}, NQO1*2(C609T), MTHFR(C677T) and TYMS 2R/3R in 78 t-AML/t-MDS and 458 normal individuals (control group, CG) using real-time and conventional polymerase chain reaction (PCR)-based methods. | 0.003452799 | 2007 | CYP3A4 | 7 | 99784371 | T | C |
| rs1800713 | 17367411 | 1576 | CYP3A4 | umls:C0023467 | BeFree | We analysed the prevalence of genetic polymorphisms of CYP1A1*2A(T6235C), CYP2E1*5B(C-1019T), CYP3A4*1B(A-290G), del{GSTT1}, del{GSTM1}, NQO1*2(C609T), MTHFR(C677T) and TYMS 2R/3R in 78 t-AML/t-MDS and 458 normal individuals (control group, CG) using real-time and conventional polymerase chain reaction (PCR)-based methods. | 0.001357209 | 2007 | CYP3A4 | 7 | 99784371 | T | C |
| rs1800713 | 17367411 | 1571 | CYP2E1 | umls:C0023467 | BeFree | We analysed the prevalence of genetic polymorphisms of CYP1A1*2A(T6235C), CYP2E1*5B(C-1019T), CYP3A4*1B(A-290G), del{GSTT1}, del{GSTM1}, NQO1*2(C609T), MTHFR(C677T) and TYMS 2R/3R in 78 t-AML/t-MDS and 458 normal individuals (control group, CG) using real-time and conventional polymerase chain reaction (PCR)-based methods. | 0.001628651 | 2007 | CYP3A4 | 7 | 99784371 | T | C |
| rs1800713 | 17761709 | 1576 | CYP3A4 | umls:C0023467 | BeFree | Carriers of both the RAD51-G135C and CYP3A4-A-290G variants were at highest AML risk (P = 0.003; OR:13,6; 95% CI: 2.0-585.5), suggesting a synergistic effect between these polymorphisms. | 0.001357209 | 2007 | CYP3A4 | 7 | 99784371 | T | C |
| rs1800713 | 17761709 | 5888 | RAD51 | umls:C0023467 | BeFree | Carriers of both the RAD51-G135C and CYP3A4-A-290G variants were at highest AML risk (P = 0.003; OR:13,6; 95% CI: 2.0-585.5), suggesting a synergistic effect between these polymorphisms. | 0.009544073 | 2007 | CYP3A4 | 7 | 99784371 | T | C |
| rs1800713 | 17367411 | 2944 | GSTM1 | umls:C0023467 | BeFree | We analysed the prevalence of genetic polymorphisms of CYP1A1*2A(T6235C), CYP2E1*5B(C-1019T), CYP3A4*1B(A-290G), del{GSTT1}, del{GSTM1}, NQO1*2(C609T), MTHFR(C677T) and TYMS 2R/3R in 78 t-AML/t-MDS and 458 normal individuals (control group, CG) using real-time and conventional polymerase chain reaction (PCR)-based methods. | 0.048997747 | 2007 | CYP3A4 | 7 | 99784371 | T | C |
| rs1801270 | 23167335 | 7157 | TP53 | umls:C0023467 | BeFree | We suggest that SNPs in the P53 pathway, especially the P21 ser31arg polymorphism and combined polymorphisms especially the P21/ MDM2 might be genetic susceptibility factors in the pathogenesis of AML. | 0.156878977 | 2012 | CDKN1A | 6 | 36684194 | C | A,T |
| rs1801270 | 23167335 | 4193 | MDM2 | umls:C0023467 | BeFree | MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia. | 0.011791553 | 2012 | CDKN1A | 6 | 36684194 | C | A,T |
| rs1805794 | 23283743 | 4683 | NBN | umls:C0023467 | BeFree | These findings indicated that rs1805794G/C polymorphism in NBS1 may play a protective role in mediating the risk of AML. | 0.000542884 | 2013 | NBN | 8 | 89978251 | C | G |
| rs1805794 | 23283743 | 55655 | NLRP2 | umls:C0023467 | BeFree | NBS1 rs1805794G>C polymorphism is associated with decreased risk of acute myeloid leukemia in a Chinese population. | 0.000542884 | 2013 | NBN | 8 | 89978251 | C | G |
| rs187729 | 24886876 | 5371 | PML | umls:C0023467 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.011943442 | 2014 | ARHGAP26 | 5 | 143226004 | C | T |
| rs187729 | 24886876 | 3394 | IRF8 | umls:C0023467 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.001628651 | 2014 | ARHGAP26 | 5 | 143226004 | C | T |
| rs187729 | 24886876 | 23092 | ARHGAP26 | umls:C0023467 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.001628651 | 2014 | ARHGAP26 | 5 | 143226004 | C | T |
| rs1982151 | 17900800 | 80010 | RMI1 | umls:C0023467 | BeFree | We have analyzed the common polymorphism Ser455Asn in RMI1 and its association with cancer risk in acute myeloid leukemia (AML, N=93), myelodysplatic syndromes (MDS, N=74), and malignant melanoma (MM, N=166). | 0.005362824 | 2007 | RMI1 | 9 | 84002350 | A | G |
| rs200945282 | 24968822 | 4869 | NPM1 | umls:C0023467 | BeFree | We describe a patient with acute myeloid leukemia (AML) who had a normal karyotype at diagnosis and was negative for NPM1 and FLT3 mutations, but had a KIT G565V mutation in exon 11. | 0.446321629 | 2014 | KIT | 4 | 54727462 | G | T |
| rs200945282 | 24968822 | 2322 | FLT3 | umls:C0023467 | BeFree | We describe a patient with acute myeloid leukemia (AML) who had a normal karyotype at diagnosis and was negative for NPM1 and FLT3 mutations, but had a KIT G565V mutation in exon 11. | 0.56 | 2014 | KIT | 4 | 54727462 | G | T |
| rs200945282 | 24968822 | 3815 | KIT | umls:C0023467 | BeFree | We describe a patient with acute myeloid leukemia (AML) who had a normal karyotype at diagnosis and was negative for NPM1 and FLT3 mutations, but had a KIT G565V mutation in exon 11. | 0.301492667 | 2014 | KIT | 4 | 54727462 | G | T |
| rs2072671 | 23287564 | 978 | CDA | umls:C0023467 | BeFree | The effect of CDA SNP A79C and gender on CDA expression, enzyme activity, and drug pharmacokinetics/pharmacodynamics was examined in mice and humans, and the impact on overall survival (OS) was evaluated in 5-azacytidine/decitabine-treated patients with MDS (n = 90) and cytarabine-treated patients with acute myeloid leukemia (AML) (n = 76). | 0.007177041 | 2013 | CDA | 1 | 20589208 | A | C |
| rs2239633 | 24564228 | 1053 | CEBPE | umls:C0023467 | BeFree | The SNPs (IKZF1 rs11978267, ARID5B rs10821936 and rs10994982, CEBPE rs2239633) were genotyped in 265 cases [169 acute lymphoblastic leukemia (ALL) and 96 acute myeloid leukaemia (AML)] and 505 controls by Taqman allelic discrimination assay. | 0.003538676 | 2014 | CEBPE | 14 | 23119848 | G | A |
| rs2239633 | 24564228 | 84159 | ARID5B | umls:C0023467 | BeFree | The SNPs (IKZF1 rs11978267, ARID5B rs10821936 and rs10994982, CEBPE rs2239633) were genotyped in 265 cases [169 acute lymphoblastic leukemia (ALL) and 96 acute myeloid leukaemia (AML)] and 505 controls by Taqman allelic discrimination assay. | 0.000271442 | 2014 | CEBPE | 14 | 23119848 | G | A |
| rs2424908 | 24069326 | 1789 | DNMT3B | umls:C0023467 | BeFree | These results suggest that DNMT3B polymorphisms may contribute to the genetic susceptibility to AML; in particular, the G allele of rs1569686 serves as a risk factor for AML, whereas the C allele of rs2424908 represents a potential protective factor. | 0.001357209 | 2013 | DNMT3B | 20 | 32772577 | C | T |
| rs2424908 | 24069326 | 6570 | SLC18A1 | umls:C0023467 | BeFree | The CGGT, CTAT, TGAT, and CGAT haplotypes of rs6087990, rs1569686, rs6119954, and rs2424908 appeared to significantly increase the AML risk, and the TTGC haplotype appeared to significantly reduce the risk. | 0.000271442 | 2013 | DNMT3B | 20 | 32772577 | C | T |
| rs2424908 | 24069326 | 7204 | TRIO | umls:C0023467 | BeFree | The CGGT, CTAT, TGAT, and CGAT haplotypes of rs6087990, rs1569686, rs6119954, and rs2424908 appeared to significantly increase the AML risk, and the TTGC haplotype appeared to significantly reduce the risk. | 0.120271442 | 2013 | DNMT3B | 20 | 32772577 | C | T |
| rs25487 | 23662987 | 7515 | XRCC1 | umls:C0023467 | BeFree | XRCC1 Arg194Trp and Arg399Gln polymorphisms are significantly associated with shorter survival in acute myeloid leukemia. | 0.00827274 | 2014 | XRCC1 | 19 | 43551574 | T | C |
| rs25487 | 12393447 | 7515 | XRCC1 | umls:C0023467 | GAD | [The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia.] | 0.00827274 | 2002 | XRCC1 | 19 | 43551574 | T | C |
| rs267606708 | 22246246 | 867 | CBL | umls:C0023467 | BeFree | We compared SFK and RTK pathway activity and inhibitors in acute myeloid leukemia cell lines containing homozygous R420Q mutation (GDM-1), heterozygous deletion (MOLM13) and wild-type (WT) CBL (THP1, U937). | 0.011073035 | 2012 | CBL | 11 | 119278541 | G | A |
| rs28931590 | NA | 1050 | CEBPA | umls:C0023467 | CLINVAR | NA | 0.553105144 | NA | CEBPA;CEBPA-AS1 | 19 | 33302164 | T | A |
| rs28934595 | 15863206 | 7036 | TFR2 | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000814326 | 2005 | HFE | 6 | 26091354 | A | C |
| rs28934595 | 15863206 | 3077 | HFE | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.001357209 | 2005 | HFE | 6 | 26091354 | A | C |
| rs28934889 | 15863206 | 7036 | TFR2 | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000814326 | 2005 | HFE | 6 | 26090921 | G | A |
| rs28934889 | 15863206 | 3077 | HFE | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.001357209 | 2005 | HFE | 6 | 26090921 | G | A |
| rs3092856 | 20232390 | 7157 | TP53 | umls:C0023467 | BeFree | Postchemotherapy response analysis revealed that AML patients heterozygous for ATM 4138C>T (rs3092856) or GG homozygous for TP53 215C>G (rs1042522) were independently linked to inferior treatment outcomes. | 0.156878977 | 2011 | ATM | 11 | 108289005 | C | T |
| rs35719940 | 25108601 | 7015 | TERT | umls:C0023467 | BeFree | Telomerase reverse transcriptase (TERT) A1062T mutation as a prognostic factor in Egyptian patients with acute myeloid leukemia (AML). | 0.124538567 | 2014 | TERT;LOC105374613 | 5 | 1254479 | C | T |
| rs373667881 | 22294728 | 10221 | TRIB1 | umls:C0023467 | BeFree | The bone marrow transfer experiment showed that acute myeloid leukemia development was accelerated by transducing murine bone marrow cells with the R107L mutant in which enhancement of ERK phosphorylation and C/EBPα degradation by Trib1 expression was even greater than in those expressing wild-type. | 0.001628651 | 2012 | TRIB1 | 8 | 125431222 | G | T |
| rs373667881 | 22294728 | 2048 | EPHB2 | umls:C0023467 | BeFree | The bone marrow transfer experiment showed that acute myeloid leukemia development was accelerated by transducing murine bone marrow cells with the R107L mutant in which enhancement of ERK phosphorylation and C/EBPα degradation by Trib1 expression was even greater than in those expressing wild-type. | 0.001628651 | 2012 | TRIB1 | 8 | 125431222 | G | T |
| rs373667881 | 22294728 | 1050 | CEBPA | umls:C0023467 | BeFree | The bone marrow transfer experiment showed that acute myeloid leukemia development was accelerated by transducing murine bone marrow cells with the R107L mutant in which enhancement of ERK phosphorylation and C/EBPα degradation by Trib1 expression was even greater than in those expressing wild-type. | 0.553105144 | 2012 | TRIB1 | 8 | 125431222 | G | T |
| rs373667881 | 22294728 | 5594 | MAPK1 | umls:C0023467 | BeFree | The bone marrow transfer experiment showed that acute myeloid leukemia development was accelerated by transducing murine bone marrow cells with the R107L mutant in which enhancement of ERK phosphorylation and C/EBPα degradation by Trib1 expression was even greater than in those expressing wild-type. | 0.002171535 | 2012 | TRIB1 | 8 | 125431222 | G | T |
| rs376588714 | 15345593 | 2322 | FLT3 | umls:C0023467 | BeFree | Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). | 0.56 | 2005 | FLT3 | 13 | 28018483 | T | C |
| rs3794845 | 20438785 | 4155 | MBP | umls:C0023467 | GAD | [Polymorphisms in innate immunity genes and risk of childhood leukemia.] | 0.002367032 | 2010 | MBP | 18 | 77002561 | G | C |
| rs386493716 | 23662987 | 7515 | XRCC1 | umls:C0023467 | BeFree | XRCC1 Arg194Trp and Arg399Gln polymorphisms are significantly associated with shorter survival in acute myeloid leukemia. | 0.00827274 | 2014 | NA | NA | NA | NA | NA |
| rs386545546 | 23662987 | 7515 | XRCC1 | umls:C0023467 | BeFree | XRCC1 Arg194Trp and Arg399Gln polymorphisms are significantly associated with shorter survival in acute myeloid leukemia. | 0.00827274 | 2014 | NA | NA | NA | NA | NA |
| rs386626619 | 16598306 | 6774 | STAT3 | umls:C0023467 | BeFree | Thus, while JAK2 V617F is uncommon in de novo AML and probably does not occur in lymphoid malignancy, unexplained STAT3 activation is common in AML. | 0.127881746 | 2006 | NA | NA | NA | NA | NA |
| rs386626619 | 22571758 | 7531 | YWHAE | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.039359071 | 2012 | NA | NA | NA | NA | NA |
| rs386626619 | 19474426 | 3717 | JAK2 | umls:C0023467 | BeFree | We selected the six patients with myelodysplastic syndromes or AML because they carried acquired rearrangements on chromosome 4q24; we selected the five patients with myeloproliferative disorders because they carried a dominant clone in hematopoietic progenitor cells that was positive for the V617F mutation in the Janus kinase 2 (JAK2) gene. | 0.284782823 | 2009 | NA | NA | NA | NA | NA |
| rs386626619 | 16598306 | 2056 | EPO | umls:C0023467 | BeFree | We hypothesized that the JAK2 V617F mutation might also be present in samples from patients with acute myeloid leukemia (AML), especially erythroleukemia (AML-M6) or megakaryoblastic leukemia (AML-M7), where it might mimic erythropoietin or thrombopoietin signaling. | 0.003181358 | 2006 | NA | NA | NA | NA | NA |
| rs386626619 | 17363731 | 4597 | MVD | umls:C0023467 | BeFree | In a second patient positive for JAK2-V617F at transformation, but with JAK2-V617F-negative leukemic blasts, we found del(11q) in all cells examined, suggesting a common clonal origin of MPD and AML. | 0.002442977 | 2007 | NA | NA | NA | NA | NA |
| rs386626619 | 22818858 | 3717 | JAK2 | umls:C0023467 | BeFree | There was a trend toward a more frequent evolution to myelofibrosis when the JAK2(V617F) mutated allele burden was >50% (p=0.09), but not to AML. | 0.284782823 | 2012 | NA | NA | NA | NA | NA |
| rs386626619 | 22571758 | 171023 | ASXL1 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.051150624 | 2012 | NA | NA | NA | NA | NA |
| rs386626619 | 22571758 | 2322 | FLT3 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.56 | 2012 | NA | NA | NA | NA | NA |
| rs386626619 | 16831057 | 3717 | JAK2 | umls:C0023467 | BeFree | JAK2(V617F) was identified in patients previously diagnosed with a myeloproliferative disorder or acute myeloid leukemia transformed from myeloproliferative disorder, whereas a wild-type genotype was identified in patients with reactive conditions or de novo acute myeloid leukemia. | 0.284782823 | 2006 | NA | NA | NA | NA | NA |
| rs386626619 | 24404189 | 1978 | EIF4EBP1 | umls:C0023467 | BeFree | Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. | 0.121628651 | 2013 | NA | NA | NA | NA | NA |
| rs386626619 | 22571758 | 3717 | JAK2 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.284782823 | 2012 | NA | NA | NA | NA | NA |
| rs386626619 | 17363731 | 3717 | JAK2 | umls:C0023467 | BeFree | In a second patient positive for JAK2-V617F at transformation, but with JAK2-V617F-negative leukemic blasts, we found del(11q) in all cells examined, suggesting a common clonal origin of MPD and AML. | 0.284782823 | 2007 | NA | NA | NA | NA | NA |
| rs386626619 | 20153505 | 3717 | JAK2 | umls:C0023467 | BeFree | A JAK2 V617F mutation was identified in one patient who had acute myeloid leukemia with concurrent mast cell disease. | 0.284782823 | 2010 | NA | NA | NA | NA | NA |
| rs386626619 | 22571758 | 23451 | SF3B1 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.040444839 | 2012 | NA | NA | NA | NA | NA |
| rs386626619 | 21786333 | 3717 | JAK2 | umls:C0023467 | BeFree | In the test of blind screening of 223 samples (111 Ph- MPNs, 60 Ph+ chronic myeloid leukemia, and 52 acute myeloid leukemia), JAK2 V617F mutations were found in 78 (70%) patients with MPNs, but in none with chronic and acute myeloid leukemia. | 0.284782823 | 2011 | NA | NA | NA | NA | NA |
| rs386626619 | 22571758 | 54790 | TET2 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.061237581 | 2012 | NA | NA | NA | NA | NA |
| rs386626619 | 22571758 | 83886 | PRSS27 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.004071628 | 2012 | NA | NA | NA | NA | NA |
| rs386626619 | 16598306 | 3717 | JAK2 | umls:C0023467 | BeFree | JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. | 0.284782823 | 2006 | NA | NA | NA | NA | NA |
| rs386626619 | 24404189 | 3717 | JAK2 | umls:C0023467 | BeFree | Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. | 0.284782823 | 2013 | NA | NA | NA | NA | NA |
| rs386626619 | 22411871 | 2322 | FLT3 | umls:C0023467 | BeFree | JAK2(V617F) and FLT3(ITD)-positive polycythemia vera cells and acute myeloid leukemia cells also produce ROS via MRC-cIII. | 0.56 | 2012 | NA | NA | NA | NA | NA |
| rs386626619 | 16408098 | 3717 | JAK2 | umls:C0023467 | BeFree | We screened 79 acute myeloid leukemia (AML) cell lines and found five positive for JAK2 V617F (HEL, MB-02, MUTZ-8, SET-2, UKE-1), 4/5 with histories of MPD/MDS. | 0.284782823 | 2006 | NA | NA | NA | NA | NA |
| rs386626619 | 22041374 | 3717 | JAK2 | umls:C0023467 | BeFree | This report describes the first case of myeloid sarcoma with JAK2 V617F mutation and implication of its progression to AML. | 0.284782823 | 2011 | NA | NA | NA | NA | NA |
| rs386626619 | 24404189 | 83886 | PRSS27 | umls:C0023467 | BeFree | PVTL-1 cells may provide a valuable model system to elucidate the molecular mechanisms involved in evolution of Jak2-V617F-expressing MPN to AML and to develop novel therapies against this intractable condition. | 0.004071628 | 2013 | NA | NA | NA | NA | NA |
| rs386626619 | 22571758 | 5048 | PAFAH1B1 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.039359071 | 2012 | NA | NA | NA | NA | NA |
| rs386626619 | 16247455 | 3717 | JAK2 | umls:C0023467 | BeFree | The JAK2 V617F mutation in de novo acute myelogenous leukemias. | 0.284782823 | 2006 | NA | NA | NA | NA | NA |
| rs386626619 | 22411871 | 3717 | JAK2 | umls:C0023467 | BeFree | JAK2(V617F) and FLT3(ITD)-positive polycythemia vera cells and acute myeloid leukemia cells also produce ROS via MRC-cIII. | 0.284782823 | 2012 | NA | NA | NA | NA | NA |
| rs386626619 | 22571758 | 861 | RUNX1 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.260873464 | 2012 | NA | NA | NA | NA | NA |
| rs386626619 | 22612514 | 3717 | JAK2 | umls:C0023467 | BeFree | As his complete blood count included a few myeloid blasts (1% of WBC) and a bone marrow biopsy detected fibrosis without evidence of acute myelogenous leukemia (AML), a diagnosis of extramedullary blastic transformation of PMF was made, which was confirmed later by V617F mutation in Janus kinase-2 in both initial bone marrow biopsy and axillary tumor biopsy specimens. | 0.284782823 | 2012 | NA | NA | NA | NA | NA |
| rs387906553 | 12384420 | 1991 | ELANE | umls:C0023467 | BeFree | To test the hypothesis that these mutations are causative for SCN, we generated transgenic mice carrying a targeted mutation of their Ela2 gene (V72M) reproducing a mutation found in 2 unrelated patients with SCN, one of whom developed AML. | 0.001085767 | 2002 | ELANE | 19 | 853022 | G | A |
| rs387907097 | NA | 343641 | TGM6 | umls:C0023467 | CLINVAR | NA | 0.120271442 | NA | TGM6 | 20 | 2417445 | T | G |
| rs397507444 | 17071478 | 4524 | MTHFR | umls:C0023467 | BeFree | Association between the MTHFR A1298C polymorphism and increased risk of acute myeloid leukemia in Brazilian children. | 0.016731045 | 2006 | MTHFR | 1 | 11794407 | T | G |
| rs398122514 | NA | 2322 | FLT3 | umls:C0023467 | CLINVAR | NA | 0.56 | NA | FLT3 | 13 | 28018487 | - | GGATCC |
| rs4793665 | 18207572 | 2944 | GSTM1 | umls:C0023467 | BeFree | We found that the ABCC3 C-211T polymorphism and GSTM1 null genotype have adverse prognostic significance in AML. | 0.048997747 | 2008 | ABCC3 | 17 | 50634726 | C | T |
| rs4793665 | 18207572 | 8714 | ABCC3 | umls:C0023467 | BeFree | We found that the ABCC3 C-211T polymorphism and GSTM1 null genotype have adverse prognostic significance in AML. | 0.012158802 | 2008 | ABCC3 | 17 | 50634726 | C | T |
| rs587776710 | NA | 2120 | ETV6 | umls:C0023467 | CLINVAR | NA | 0.2605735 | NA | ETV6 | 12 | 11890994 | - | GGG |
| rs587776806 | NA | 4869 | NPM1 | umls:C0023467 | CLINVAR | NA | 0.446321629 | NA | NPM1 | 5 | 171410543 | - | CATG,CCTG,CGTG,TCTG |
| rs587776848 | NA | 1050 | CEBPA | umls:C0023467 | CLINVAR | NA | 0.553105144 | NA | CEBPA;CEBPA-AS1 | 19 | 33302294 | GCGCGGG | - |
| rs587776849 | NA | 1050 | CEBPA | umls:C0023467 | CLINVAR | NA | 0.553105144 | NA | CEBPA;CEBPA-AS1 | 19 | 33302204 | - | CGGC |
| rs606231202 | NA | 3845 | KRAS | umls:C0023467 | CLINVAR | NA | 0.129087065 | NA | KRAS | 12 | 25245355 | - | CCA |
| rs6087990 | 24069326 | 6570 | SLC18A1 | umls:C0023467 | BeFree | The CGGT, CTAT, TGAT, and CGAT haplotypes of rs6087990, rs1569686, rs6119954, and rs2424908 appeared to significantly increase the AML risk, and the TTGC haplotype appeared to significantly reduce the risk. | 0.000271442 | 2013 | DNMT3B | 20 | 32762102 | T | C |
| rs6087990 | 24069326 | 7204 | TRIO | umls:C0023467 | BeFree | The CGGT, CTAT, TGAT, and CGAT haplotypes of rs6087990, rs1569686, rs6119954, and rs2424908 appeared to significantly increase the AML risk, and the TTGC haplotype appeared to significantly reduce the risk. | 0.120271442 | 2013 | DNMT3B | 20 | 32762102 | T | C |
| rs6119954 | 24069326 | 7204 | TRIO | umls:C0023467 | BeFree | The CGGT, CTAT, TGAT, and CGAT haplotypes of rs6087990, rs1569686, rs6119954, and rs2424908 appeared to significantly increase the AML risk, and the TTGC haplotype appeared to significantly reduce the risk. | 0.120271442 | 2013 | DNMT3B | 20 | 32776360 | G | A |
| rs6119954 | 24069326 | 6570 | SLC18A1 | umls:C0023467 | BeFree | The CGGT, CTAT, TGAT, and CGAT haplotypes of rs6087990, rs1569686, rs6119954, and rs2424908 appeared to significantly increase the AML risk, and the TTGC haplotype appeared to significantly reduce the risk. | 0.000271442 | 2013 | DNMT3B | 20 | 32776360 | G | A |
| rs662 | 22976839 | 5444 | PON1 | umls:C0023467 | BeFree | The NQO1 rs1800566 (C609T), PON1 rs854560 (L55M), and PON1 rs662 (Q192R) polymorphisms modified risk depending on leukemia subtype (decreased in AML, increased and decreased in ALL, respectively), age strata, and variant genotype combinations. | 0.000271442 | 2012 | PON1 | 7 | 95308134 | T | C |
| rs703817 | 20438785 | 6778 | STAT6 | umls:C0023467 | GAD | [Polymorphisms in innate immunity genes and risk of childhood leukemia.] | 0.002367032 | 2010 | STAT6 | 12 | 57096045 | C | T |
| rs74315450 | 21725049 | 861 | RUNX1 | umls:C0023467 | BeFree | We performed analysis of hematopoiesis from 2 FPD/AML pedigrees with 2 distinct RUNX1 germline mutations, that is, the R139X in a pedigree without AML and the R174Q mutation in a pedigree with AML. | 0.260873464 | 2011 | RUNX1 | 21 | 34859485 | C | T |
| rs74315450 | 20694842 | 861 | RUNX1 | umls:C0023467 | BeFree | RUNX1, which regulates a gene for hematopoiesis, is frequently mutated in AML and, in this study, one out of three patients showed the mutation R174Q in RUNX1. | 0.260873464 | 2010 | RUNX1 | 21 | 34859485 | C | T |
| rs762890562 | NA | 51428 | DDX41 | umls:C0023467 | CLINVAR | NA | 0.120542884 | NA | DDX41 | 5 | 177515944 | - | CATC |
| rs77375493 | 16831057 | 3717 | JAK2 | umls:C0023467 | BeFree | JAK2(V617F) was identified in patients previously diagnosed with a myeloproliferative disorder or acute myeloid leukemia transformed from myeloproliferative disorder, whereas a wild-type genotype was identified in patients with reactive conditions or de novo acute myeloid leukemia. | 0.284782823 | 2006 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 16247455 | 3717 | JAK2 | umls:C0023467 | BeFree | The JAK2 V617F mutation in de novo acute myelogenous leukemias. | 0.284782823 | 2006 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22571758 | 2322 | FLT3 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.56 | 2012 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22411871 | 3717 | JAK2 | umls:C0023467 | BeFree | JAK2(V617F) and FLT3(ITD)-positive polycythemia vera cells and acute myeloid leukemia cells also produce ROS via MRC-cIII. | 0.284782823 | 2012 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 17363731 | 3717 | JAK2 | umls:C0023467 | BeFree | In a second patient positive for JAK2-V617F at transformation, but with JAK2-V617F-negative leukemic blasts, we found del(11q) in all cells examined, suggesting a common clonal origin of MPD and AML. | 0.284782823 | 2007 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22571758 | 5048 | PAFAH1B1 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.039359071 | 2012 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22612514 | 3717 | JAK2 | umls:C0023467 | BeFree | As his complete blood count included a few myeloid blasts (1% of WBC) and a bone marrow biopsy detected fibrosis without evidence of acute myelogenous leukemia (AML), a diagnosis of extramedullary blastic transformation of PMF was made, which was confirmed later by V617F mutation in Janus kinase-2 in both initial bone marrow biopsy and axillary tumor biopsy specimens. | 0.284782823 | 2012 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22571758 | 83886 | PRSS27 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.004071628 | 2012 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 17363731 | 4597 | MVD | umls:C0023467 | BeFree | In a second patient positive for JAK2-V617F at transformation, but with JAK2-V617F-negative leukemic blasts, we found del(11q) in all cells examined, suggesting a common clonal origin of MPD and AML. | 0.002442977 | 2007 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22818858 | 3717 | JAK2 | umls:C0023467 | BeFree | There was a trend toward a more frequent evolution to myelofibrosis when the JAK2(V617F) mutated allele burden was >50% (p=0.09), but not to AML. | 0.284782823 | 2012 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 24404189 | 1978 | EIF4EBP1 | umls:C0023467 | BeFree | Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. | 0.121628651 | 2013 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22571758 | 861 | RUNX1 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.260873464 | 2012 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 16598306 | 2056 | EPO | umls:C0023467 | BeFree | We hypothesized that the JAK2 V617F mutation might also be present in samples from patients with acute myeloid leukemia (AML), especially erythroleukemia (AML-M6) or megakaryoblastic leukemia (AML-M7), where it might mimic erythropoietin or thrombopoietin signaling. | 0.003181358 | 2006 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22571758 | 23451 | SF3B1 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.040444839 | 2012 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22571758 | 171023 | ASXL1 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.051150624 | 2012 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22571758 | 54790 | TET2 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.061237581 | 2012 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 16598306 | 6774 | STAT3 | umls:C0023467 | BeFree | Thus, while JAK2 V617F is uncommon in de novo AML and probably does not occur in lymphoid malignancy, unexplained STAT3 activation is common in AML. | 0.127881746 | 2006 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 24404189 | 83886 | PRSS27 | umls:C0023467 | BeFree | PVTL-1 cells may provide a valuable model system to elucidate the molecular mechanisms involved in evolution of Jak2-V617F-expressing MPN to AML and to develop novel therapies against this intractable condition. | 0.004071628 | 2013 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22411871 | 2322 | FLT3 | umls:C0023467 | BeFree | JAK2(V617F) and FLT3(ITD)-positive polycythemia vera cells and acute myeloid leukemia cells also produce ROS via MRC-cIII. | 0.56 | 2012 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 16408098 | 3717 | JAK2 | umls:C0023467 | BeFree | We screened 79 acute myeloid leukemia (AML) cell lines and found five positive for JAK2 V617F (HEL, MB-02, MUTZ-8, SET-2, UKE-1), 4/5 with histories of MPD/MDS. | 0.284782823 | 2006 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 20153505 | 3717 | JAK2 | umls:C0023467 | BeFree | A JAK2 V617F mutation was identified in one patient who had acute myeloid leukemia with concurrent mast cell disease. | 0.284782823 | 2010 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 21786333 | 3717 | JAK2 | umls:C0023467 | BeFree | In the test of blind screening of 223 samples (111 Ph- MPNs, 60 Ph+ chronic myeloid leukemia, and 52 acute myeloid leukemia), JAK2 V617F mutations were found in 78 (70%) patients with MPNs, but in none with chronic and acute myeloid leukemia. | 0.284782823 | 2011 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22571758 | 7531 | YWHAE | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.039359071 | 2012 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 24404189 | 3717 | JAK2 | umls:C0023467 | BeFree | Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. | 0.284782823 | 2013 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22041374 | 3717 | JAK2 | umls:C0023467 | BeFree | This report describes the first case of myeloid sarcoma with JAK2 V617F mutation and implication of its progression to AML. | 0.284782823 | 2011 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22571758 | 3717 | JAK2 | umls:C0023467 | BeFree | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). | 0.284782823 | 2012 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 19474426 | 3717 | JAK2 | umls:C0023467 | BeFree | We selected the six patients with myelodysplastic syndromes or AML because they carried acquired rearrangements on chromosome 4q24; we selected the five patients with myeloproliferative disorders because they carried a dominant clone in hematopoietic progenitor cells that was positive for the V617F mutation in the Janus kinase 2 (JAK2) gene. | 0.284782823 | 2009 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 16598306 | 3717 | JAK2 | umls:C0023467 | BeFree | JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. | 0.284782823 | 2006 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs797046041 | NA | 7015 | TERT | umls:C0023467 | CLINVAR | NA | 0.124538567 | NA | TERT | 5 | 1282578 | G | C |
| rs80338880 | 15863206 | 3077 | HFE | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.001357209 | 2005 | TFR2;LOC105375428 | 7 | 100633100 | G | C |
| rs80338880 | 15863206 | 7036 | TFR2 | umls:C0023467 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000814326 | 2005 | TFR2;LOC105375428 | 7 | 100633100 | G | C |
| rs854560 | 22976839 | 5444 | PON1 | umls:C0023467 | BeFree | The NQO1 rs1800566 (C609T), PON1 rs854560 (L55M), and PON1 rs662 (Q192R) polymorphisms modified risk depending on leukemia subtype (decreased in AML, increased and decreased in ALL, respectively), age strata, and variant genotype combinations. | 0.000271442 | 2012 | PON1 | 7 | 95316772 | A | C,G,N,T |
| rs861539 | 23747401 | 7517 | XRCC3 | umls:C0023467 | BeFree | XRCC3 Thr241Met polymorphism and risk of acute myeloid leukemia in a Romanian population. | 0.012268423 | 2013 | KLC1;XRCC3 | 14 | 103699416 | G | A |
| rs861539 | 24197983 | 7517 | XRCC3 | umls:C0023467 | BeFree | The XRCC3 Thr241Met polymorphism might be associated with risk of leukemia in AML. | 0.012268423 | 2013 | KLC1;XRCC3 | 14 | 103699416 | G | A |
| rs861539 | 12393447 | 7517 | XRCC3 | umls:C0023467 | GAD | [The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia.] | 0.012268423 | 2002 | KLC1;XRCC3 | 14 | 103699416 | G | A |
| rs9479 | 24886876 | 3394 | IRF8 | umls:C0023467 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.001628651 | 2014 | PML | 15 | 74036235 | A | G |
| rs9479 | 24886876 | 5371 | PML | umls:C0023467 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.011943442 | 2014 | PML | 15 | 74036235 | A | G |
| rs9479 | 24886876 | 23092 | ARHGAP26 | umls:C0023467 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.001628651 | 2014 | PML | 15 | 74036235 | A | G |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:28) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0023467 | alitretinoin | C103303 | 5300/3/8 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 10536188 | ||
| C0023467 | allopurinol | D000493 | 315-30-0 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 12708945 | ||
| C0023467 | amsacrine | D000677 | - | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 15148258 | ||
| C0023467 | arsenic trioxide | C006632 | 1327-53-3 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 12931215 | ||
| C0023467 | azacitidine | D001374 | 320-67-2 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 17596541 | ||
| C0023467 | bortezomib | D000069286 | - | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 18166786 | ||
| C0023467 | busulfan | D002066 | 55-98-1 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 11069031 | ||
| C0023467 | chloramphenicol | D002701 | 56-75-7 | leukemia, myeloid, acute | MESH:D015470 | marker/mechanism | 4726970 | ||
| C0023467 | cladribine | D017338 | 4291-63-8 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 7948311 | ||
| C0023467 | chloroquine | D002738 | 1954/5/7 | leukemia, myeloid, acute | MESH:D015470 | marker/mechanism | 273209 | ||
| C0023467 | crizotinib | C551994 | - | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 22683780 | ||
| C0023467 | cyclophosphamide | D003520 | 50-18-0 | leukemia, myeloid, acute | MESH:D015470 | marker/mechanism | 3352696 | ||
| C0023467 | decitabine | C014347 | 2353-33-5 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 14604977 | ||
| C0023467 | calcitriol | D002117 | 32222-06-3 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 2416438 | ||
| C0023467 | hydroxyurea | D006918 | 127-07-1 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 12708945 | ||
| C0023467 | ifosfamide | D007069 | 3778-73-2 | leukemia, myeloid, acute | MESH:D015470 | marker/mechanism | 16985182 | ||
| C0023467 | indomethacin | D007213 | 53-86-1 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 18360721 | ||
| C0023467 | medroxyprogesterone acetate | D017258 | 71-58-9 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 19158949 | ||
| C0023467 | methotrexate | D008727 | 1959/5/2 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 1058041 | ||
| C0023467 | mitoxantrone | D008942 | 65271-80-9 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 10813714 | ||
| C0023467 | paclitaxel | D017239 | - | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 9766754 | ||
| C0023467 | ponatinib | C545373 | - | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 21482694 | ||
| C0023467 | sorafenib | C471405 | - | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 18200035 | ||
| C0023467 | thalidomide | D013792 | 50-35-1 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 18720364 | ||
| C0023467 | tretinoin | D014212 | 302-79-4 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 16294345 | ||
| C0023467 | troglitazone | C057693 | 97322-87-7 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 10536188 | ||
| C0023467 | valproic acid | D014635 | 99-66-1 | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 16294345 | ||
| C0023467 | vincristine | D014750 | - | leukemia, myeloid, acute | MESH:D015470 | therapeutic | 4294312 | ||
FDA approved drug and dosage information(Total Drugs:0) | |
|---|---|
| (Waiting for update.) | |
FDA labeling changes(Total Drugs:0) | |
|---|---|
| (Waiting for update.) | |